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least costly per patient treated and least effective was EAS
using ranitidine ($79, 44% SF), followed by EAS using
omeprazole ($122, 50% SF), CanDys using omeprazole
($165, 52% SF), and PE using omeprazole ($562, 61%
SF). The CanDys and PE strategies using ranitidine were
both standard-dominated therapies, being less effective
and more costly than EAS using omeprazole. Results were
robust to many sensitivity analyses with PE omeprazole
remaining more effective at four weeks but much more
expensive than CanDys omeprazole. CONCLUSIONS:
The CanDys approach using omeprazole is more effective
and more costly than EAS using either omeprazole or ran-
itidine, and is less effective but much less costly than PE
using omeprazole. The time horizon of the model must
be extended to further assess the cost-effectiveness of
these approaches.
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OBJECTIVES: The aim of this study was to estimate the
cost-effectiveness of endoscopic sclerotherapy (ES) vs. lig-
ation (EL) in prevention of rebleeding in children with
oesophageal varices (OEV) from a Polish hospital per-
spective. METHODS: Retrospective analysis in 235 con-
secutive children with OEV treated with ES (206) or EL
(29) was performed to quantify effectiveness and costs 
of alternative treatments. End-points of analysis were:
variceal obliteration, referral to surgery or death. Varices
were deﬁned as “obliterated” when were too small to be
treated by endoscopic methods. The effectiveness measure
was percentage of obliteration of OEV after ES and EL
respectively. Only direct medical costs resulting from the
ES and EL, treatment of rebleeding before obliteration,
complications and crossover from ES to EL, or from
endoscopy to surgery for treatment failures were assessed.
The costs were determined from actual resource con-
sumption on a patients-speciﬁc basis and estimated using
local data on unit costs. Uni- and multivariate and
extreme scenario sensitivity analyses were performed.
RESULTS: Obliteration of varices was achieved in 65%
of children treated with ES and 90% treated with EL (p
< 0.01). The number of endoscopic procedures, bleedings,
oesophageal dilatations and surgery per patient for ES
and EL was 8.2 vs. 2.2; 1.3 vs. 0.2; 0.1 vs. 0.0; 0.2 vs.
0.07, respectively (p < 0.05). The mean cost per patient
was 16,577 PLN in ES and 3 742 PLN in EL group (1
PLN = 4 USD). The threshold analysis suggests, that EL
would lose the dominance, when the mean number of
bleedings/patient decreased two-fold in ES group and
increased ten-fold in EL group. CONCLUSION: Since EL
in comparison to ES resulted in a better effect at a lower
cost, this method was considered to be dominant for chil-
dren with OEV.
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OBJECTIVES: To determine proton pump inhibitor 
(PPI) utilization and their effect on treatment costs in
patients with gastroesophageal reﬂux disease (GERD).
METHODS: Data were extracted from National Health
Insurance Health Care claims database in Taiwan. We
identiﬁed continuously enrolled patients diagnosed with
GERD and newly treated with a PPI between Jan 1, 2001
and Dec 31, 2001. Data were analyzed for six months
following PPI initiation. Results were stratiﬁed by ﬁrst PPI
ﬁlled during the study period. GERD severity groupings
were measured using a 4-step scale ranging from an endo-
scopic diagnosis of mild esophagitis to stricture. Compli-
ance (as measured by a medication possession ratio),
length of therapy (using total days supplied ) and daily
average consumption (as measured as number of units
consumed per day) were measured. Regression analysis
was performed on GERD-related costs using treatment
patterns, type of PPI drug, and compliance as indepen-
dent variables of interest. RESULTS: Of 1600 remained
subjects for study, there are 790 (49.4%) omeprazole,
666 (41.6%) lansoprazole, and 144 (9.0%) pantoprazole
subjects. The possession ratio was not signiﬁcantly dif-
ferent between drug subjects. The mean (median) length
of therapy of omeprazole subjects was 76 (56) days, 55
(42) days for lansoprazole subjects and 56 (49) days 
for pantoprazole subjects. Among subjects pantoprazole
users did not have a lower daily average consumption
(1.00) versus both lansoprazole (1.01) and omeprazole
subjects (1.03, p = 0 .057). Compliance with PPI therapy
had 45.1% higher GERD-related pharmacy costs (p <
.001) and 40.4% higher GERD-related total costs (p <
.01). Omeprazole subjects had 17.8% higher GERD-
related pharmacy costs versus pantoprazole subjects (p <
.001). Lansoproazole subjects had 12.7% higher GERD-
related total costs versus pantoprazole subjects (p < .01),
while Omeprazole subjects had 24.9% higher GERD-
related total costs versus pantoprazole subjects (p < .001).
CONCLUSIONS: Compliance was not signiﬁcantly dif-
ferent between the PPIs, nor did increased compliance
decrease GERD-related costs. Pantoprazole subjects had
lower GERD-related costs, compared to lansoprazole and
omeprazole subjects.
